Howard Capital Management Raises Position in Pfizer Inc. (PFE)
Howard Capital Management raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 85,241 shares of the biopharmaceutical company’s stock after buying an additional 51 shares during the period. Howard Capital Management’s holdings in Pfizer were worth $3,001,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the stock. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares in the last quarter. Financial Strategy Network LLC acquired a new stake in shares of Pfizer during the first quarter valued at about $205,000. Oakmont Partners LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $211,000. Finally, Arete Wealth Advisors LLC boosted its stake in shares of Pfizer by 11.3% in the first quarter. Arete Wealth Advisors LLC now owns 7,172 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 726 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded down 0.94% on Thursday, hitting $32.76. 24,181,890 shares of the company’s stock were exchanged. The company has a market cap of $198.71 billion, a PE ratio of 29.04 and a beta of 0.86. The company’s 50-day moving average price is $34.14 and its 200-day moving average price is $34.26. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.56 earnings per share. Analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
Several analysts have recently issued reports on PFE shares. Jefferies Group decreased their target price on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 20th. Deutsche Bank AG reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, June 15th. Vetr downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target on the stock. in a report on Tuesday, June 28th. Sanford C. Bernstein set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. set a $54.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 25th. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Pfizer presently has an average rating of “Buy” and a consensus target price of $38.66.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.